Department of Hematology, Stanford University School of Medicine, Stanford, California.
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Am J Hematol. 2019 Jul;94(7):803-811. doi: 10.1002/ajh.25484. Epub 2019 May 1.
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.
优化缓解后治疗方案以维持完全缓解并防止复发是治疗急性髓系白血病（AML）患者的主要挑战。监测患者的微小残留病（MRD）有助于识别有复发风险的患者。去甲基化药物正被作为缓解后治疗进行研究。识别驱动疾病进展的复发性遗传改变，使我们能够为 AML 患者设计新的、个性化的治疗方法。新出现的数据表明，单独或联合化疗的靶向缓解后治疗可能改善结局。正在进行的临床试验结果将进一步确定潜在的临床获益。
